PE20010494A1 - Piridazinas sustituidas y piridazinas fusionadas con actividad inhibidora de la angiogenesis - Google Patents

Piridazinas sustituidas y piridazinas fusionadas con actividad inhibidora de la angiogenesis

Info

Publication number
PE20010494A1
PE20010494A1 PE2000000799A PE0007992000A PE20010494A1 PE 20010494 A1 PE20010494 A1 PE 20010494A1 PE 2000000799 A PE2000000799 A PE 2000000799A PE 0007992000 A PE0007992000 A PE 0007992000A PE 20010494 A1 PE20010494 A1 PE 20010494A1
Authority
PE
Peru
Prior art keywords
alkyl
pyridazines
ring
substitute
nr3cor6
Prior art date
Application number
PE2000000799A
Other languages
English (en)
Spanish (es)
Inventor
Stephen James Boyer
Jacques P Dumas
Holia N Hatoum-Mokdad
Teddy Kite Joe
Ning Su
Wendy Lee
Dhanapalan Nagarathnam
Robert N Sibley
Harold C E Kluender
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of PE20010494A1 publication Critical patent/PE20010494A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PE2000000799A 1999-08-10 2000-08-08 Piridazinas sustituidas y piridazinas fusionadas con actividad inhibidora de la angiogenesis PE20010494A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37132299A 1999-08-10 1999-08-10

Publications (1)

Publication Number Publication Date
PE20010494A1 true PE20010494A1 (es) 2001-06-27

Family

ID=23463486

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000799A PE20010494A1 (es) 1999-08-10 2000-08-08 Piridazinas sustituidas y piridazinas fusionadas con actividad inhibidora de la angiogenesis

Country Status (19)

Country Link
EP (1) EP1208096B1 (enExample)
JP (1) JP2003506447A (enExample)
KR (1) KR20020019969A (enExample)
CN (1) CN1378543A (enExample)
AR (1) AR025068A1 (enExample)
AT (1) ATE265448T1 (enExample)
AU (1) AU775237B2 (enExample)
BR (1) BR0013113A (enExample)
CA (1) CA2381621A1 (enExample)
CO (1) CO5180637A1 (enExample)
DE (1) DE60010280T2 (enExample)
ES (1) ES2219382T3 (enExample)
IL (1) IL147885A0 (enExample)
MX (1) MXPA02001324A (enExample)
NO (1) NO20020569L (enExample)
NZ (1) NZ517087A (enExample)
PE (1) PE20010494A1 (enExample)
WO (1) WO2001010859A1 (enExample)
ZA (1) ZA200200691B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689883B1 (en) 1999-09-28 2004-02-10 Bayer Pharmaceuticals Corporation Substituted pyridines and pyridazines with angiogenesis inhibiting activity
AR025752A1 (es) * 1999-09-28 2002-12-11 Bayer Corp Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
US7977333B2 (en) 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
GB0111078D0 (en) 2001-05-04 2001-06-27 Novartis Ag Organic compounds
EP1712234B1 (en) * 2001-09-12 2009-01-28 Novartis AG Use of 4-Pyridylmethylphthalazines for Renal Cancer Treatment
CA2471314A1 (en) * 2001-12-21 2003-07-24 Bayer Pharmaceuticals Corporation Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
AU2003249369A1 (en) * 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
CN100372535C (zh) * 2002-09-24 2008-03-05 诺瓦提斯公司 4-吡啶基甲基-酞嗪衍生物在制备治疗骨髓增生异常综合征的药物中的用途
AU2003288034A1 (en) * 2002-11-12 2004-06-03 Novartis Ag Treatment of mesothelioma
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
ES2470341T3 (es) 2007-04-05 2014-06-23 Amgen, Inc Moduladores de la aurora cinasa y método de uso
PL2167549T3 (pl) 2007-06-19 2013-03-29 Rynel Inc Materiały zawierające cząstki polimeru rozpuszczalnego w wodzie oraz sposoby ich wytwarzania i stosowania
AU2009226024B2 (en) 2008-03-20 2012-07-12 Amgen Inc. Aurora kinase modulators and method of use
CA2732101C (en) * 2008-08-04 2013-09-17 Amgen Inc. Aurora kinase modulators and methods of use
WO2010019473A1 (en) 2008-08-14 2010-02-18 Amgen Inc. Aurora kinase modulators and methods of use
CN117355303A (zh) * 2021-01-28 2024-01-05 佛罗里达大学研究基金会公司 化合物及其用于治疗神经退行性、退行性和代谢病症的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd １―（３―ピリジルメチル）フタラジン誘導体
JPH0673022A (ja) * 1992-08-27 1994-03-15 Kumiai Chem Ind Co Ltd ピリミジンまたはトリアジン誘導体及び除草剤
EP0722936B1 (en) * 1994-08-09 2004-05-19 Eisai Co., Ltd. Fused pyridazine compound
JP3919835B2 (ja) * 1994-08-09 2007-05-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合ピリダジン系化合物
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
ATE329596T1 (de) * 1999-03-30 2006-07-15 Novartis Pharma Gmbh Phthalazinderivate zur behandlung von entzündlicher erkrankungen

Also Published As

Publication number Publication date
AU775237B2 (en) 2004-07-22
ES2219382T3 (es) 2004-12-01
NO20020569L (no) 2002-04-10
DE60010280D1 (de) 2004-06-03
MXPA02001324A (es) 2002-07-22
CO5180637A1 (es) 2002-07-30
ATE265448T1 (de) 2004-05-15
JP2003506447A (ja) 2003-02-18
NZ517087A (en) 2004-05-28
AU6895400A (en) 2001-03-05
CA2381621A1 (en) 2001-02-15
BR0013113A (pt) 2002-04-30
EP1208096A1 (en) 2002-05-29
IL147885A0 (en) 2002-08-14
AR025068A1 (es) 2002-11-06
EP1208096B1 (en) 2004-04-28
KR20020019969A (ko) 2002-03-13
ZA200200691B (en) 2003-10-29
NO20020569D0 (no) 2002-02-05
CN1378543A (zh) 2002-11-06
WO2001010859A1 (en) 2001-02-15
DE60010280T2 (de) 2009-10-15

Similar Documents

Publication Publication Date Title
ATE123771T1 (de) Stickstoff enthaltende heterozyklische verbindungen, ihre herstellung und verwendung.
ATE139233T1 (de) Annelierte thiophen-derivate, ihre herstellung und verwendung
CO5060482A1 (es) Derivados terapeuticos de biarilo
PE52499A1 (es) Ftalazinas
NO178067C (no) Analogifremgangsmåte til fremstilling av terapautisk aktive heterocykliske forbindelser
AR021297A1 (es) 2-fenilbenzimidazoles y 2-fenilindoles, su preparacion y aplicacion
GR3006247T3 (enExample)
MY126586A (en) Carbamic acid derivatives and their use as metabotropic glutamate receptor ligands
CA2404125A1 (en) Sulphonamido-substituted bridged bicycloalkyl derivatives
DK0470039T3 (da) 3-arylindol- og 3-arylindazolforbindelser
KR880002829A (ko) 디하이드로피리딘 항알러지제 및 소염제
KR880013920A (ko) 디하이드로피리딘 화합물 및 이의 제조방법
DE3776044D1 (de) Pyridazinon-derivate.
EP0598123A4 (en) PIPERAZINE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING THEM.
NO177993C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive amin-derivater
KR910000755A (ko) 세로토닌 2-수용체 길항활성을 갖는 헤테로사이클릭 화합물
DE68926810D1 (de) Benzoxazepinon-Verfahren
ATE137747T1 (de) Aminobenzolverbindungen, herstellung und verwendung
AR027035A1 (es) Pirroles sustituidos
ES2112470T3 (es) Derivados de piridazinona, procedimientos de produccion y utilizacion.
EG19396A (en) Pesticidal heterocyclic compounds
KR890000478A (ko) 에르골린 유도체
KR940007008A (ko) 1, 3, 4-벤조트리아제핀-5(4h)-온 유도체 및 이것의 제조 방법
GEP19970838B (en) Process for obtaining 3-(methyltio, methylsulphinyl or methylsulphonyl)-4-quinolone
KR880010771A (ko) 이미다졸-2-티온 화합물로 제관류 손상을 경감시키는 방법

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
AE Restoration of lapsed or forfeited application
FC Refusal